3. Ramalingam SS, CIuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J Clin Onc...
3. Ramalingam SS, CIuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J Clin Oncol. 2020;38(suppl 15):9500-9500. doi:10.1200/JCO.2020.3...
参考文献：Kien Hung Do et al, PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature, Respirol Case Rep. 2023 May 3.
3. Ramalingam SS, CIuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J Clin Oncol. 2020;38(suppl 15):9500-9500. doi:10.1200/JCO.2020.3...
Lung Cancer. 2016;99:117-119.Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117-119....
Background : Metastatic triple-negative breast cancer (mTNBC) is associated with poor prognosis, and chemotherapy remains the mainstay of treatment. Cancer immunotherapy represents a promising treatment approach for mTNBC, which is chara... S Adams,J Diamond,E Hamilton,... - 《Cancer Research》 ...
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint...
PD-L1Negative (Nomembranousstaining) GainorJFetal,JClinOncol33,2015(abstr8012) Ph3programwithAtezoin1LNSCLC IMpower150Atezo+Carbo+Pac Non-squamousAtezo+Carbo+Pac+Avastin2017(PFS) n1200Carbo+Pac+Avastin IMpower130Atezo+Carbo+Nab-pac Non-squamous2017(PFS) ...
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may ...
For example, >50% PDL1+ tumour cells for treatment of non-small-cell lung cancer with pembrolizumab monotherapy. By contrast, a complementary diagnostic assay is used by clinicians to aid in risk–benefit analysis of treatment decisions but it is not required for use of the therapeutic. ...